Insulin and lipid metabolism: new developments in drug therapy

Bibliography

• ALBERTI KGMM, HOCKADAY TDR: Diabetes mellitus. In:Oxford Textbook of Medicine (2nd Edition). Weatherall eta]. (Eds.), Oxford University Press, Oxford (1987).
   Google Scholar
• DEFRONZO RA, BONADONNA RC, FERRANNINI E: Pathogenesis of NIDDM: a balanced overview. Diab. Care (1992) 15:318-367. Important and comprehensive review.
   Google Scholar
• MORRIS AD, PETRIE JR, CONNELL JMC: Insulin and hy-pertension. J. Hypertens. (1994) 12:633–642.
   PubMed Web of Science ®Google Scholar
• ROBBINS DC, ANDERSEN L, BOWSHER R eta].: Report of the American Diabetes Association's task force on standardisation of the insulin assay. Diabetes (1996) 45:242–256.
   PubMed Web of Science ®Google Scholar
• SHEN S-W, BRESSLER R: Drug therapy: clinical pharma-cology of oral antidiabetic agents. NewEngI J. Med. (1977) 296:787–793.
   PubMed Web of Science ®Google Scholar
• DEFRONZO RA, TOBIN J, ANDRES R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physic)]. (1979) 237:E214-E223. Key methodological paper.
   Google Scholar
• HOLLENBECK G, REAVEN GM: Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J. Clin. Endocrin. Metab. (1987) 64:1169–1173.
   PubMed Web of Science ®Google Scholar
• MOLLER DE, FLIER JS: Insulin resistance - mechanisms,syndromes and implications. New Engl. J. Med. (1991) 325:938–948.
   PubMed Web of Science ®Google Scholar
• REAVEN GM: Role of insulin resistance in human disease. Diabetes (1988) 37:1495-1507. Seminal synthesis of mostly previously available information on insulin resistance in asymptomatic individuals.
   Google Scholar
• LEAHY JL: Natural history of beta cell dysfunction in NIDDM. Diab. Care (1990) 13:992–1010.
   PubMed Web of Science ®Google Scholar
• RANDLE PJ, GARLAND PB, HALES CN, NEWSHOLME EA:
   Google Scholar
• •The glucose-fatty acid cycle. Lancet (1963) 1:785-790. Original physiological description of a mechanism by which glucose and free fatty acid metabolism interact.
   Google Scholar
• AUSTIN MA, EDWARDS KL: Small, dense low density lipoproteins, the insulin resistance syndrome and non-insulin dependent diabetes. Curr. Opin. Lipidol (1996) 7:167–171.
   PubMed Web of Science ®Google Scholar
• FRAYN KN, WILLIAMS CM, ARNERP: Are increased plasmanon-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? Clin. Sci. (1996) 90:243–253.
   Google Scholar
• PAOLISSO G, GAMBARDELLA A, TAGLIAMONTE MR eta].: Does free fatty acid infusion impair insulin action also through an increase in oxidative stress?' Clin. Endocrin. Metab. (1996) 81:4244–4248.
   Google Scholar
• CHIN JH, AZHAR S, HOFFMAN BB: Inactivation of endo-thelial derived relaxing factor by oxidised lipoprotein. Clin. Invest (1992) 89:10–18.
   Google Scholar
• KEANEY JF, JR., GAZIANO JM, XU A eta].: Dietary anti-oxi-dants preserve endothelium-dependent vessel relaxa-tion in cholesterol-fed rabbits. Proc. Natl. Acad. Sci. USA (1993) 90:11880–11884.
   Google Scholar
• WITZUM JL: Susceptibility of low-density lipoprotein tooxidative modification. Am. J. Med. (1993) 94:348–349.
   Google Scholar
• OLEFSKY JM, KOLTERMAN OG: Mechanisms of insulin resistance in obesity and non-insulin-dependent (type 2) diabetes mellitus. Am. J. Med. (1981) 70:151–168.
   PubMed Web of Science ®Google Scholar
• BONADONNA RC, GROOP LC, KRAEMER N: Obesity and insulin resistance in humans: a dose-response study. Metabolism (1990) 39:452–459.
   PubMed Web of Science ®Google Scholar
• FERRANNINI E, BUZZICOLI G, BONADONNA R et al.:
   Google Scholar
• •Insulin resistance in essential hypertension. New Engl. J. Med. (1987) 317:350-357. First study to demonstrate insulin resistance in essential hypertension using the euglycaemic clamp technique.
   Google Scholar
• DESPRES J-P, LAMARCHE B, MAURIEGE P et al.: Hyperin- sulinaemia as an independent risk factor for ischaemic heart disease. New Eng]. J. Med. (1996) 334:952–957.
   PubMed Web of Science ®Google Scholar
• UTRIAINEN TR, MALMSTROM S, MAKIMATTILA S, YKI-JARVINEN H: Methodological aspects and dose-response characteristics and causes of inter-individual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia (1995) 38:555–564.
   PubMed Web of Science ®Google Scholar
• BRANDS MW, MIZELLE HL, GAILLARD DA et al.: The haemodynamic response to chronic hyperinsulinae-mia in conscious dogs. Am. J. Hypertens. (1991) 4:164–168.
   PubMed Web of Science ®Google Scholar
• ANDERSON EA, MARK AL: The vasodilator action of insulin: implications for the insulin hypothesis of hy-pertension. Hypertension (1993) 21:136–141.
   PubMed Web of Science ®Google Scholar
• BARON AD, BRECHTEL-HOOK G, JOHNSTON A, HARDIN D: Skeletal muscle blood flow: a possible link between insulin resistance and blood pressure. Hypertension (1993) 21:129–135.
   PubMed Web of Science ®Google Scholar
• PETRIE JR, UEDA S, WEBB DJ et al.: Endothelial nitric oxide production and insulin sensitivity: a physiologi-cal link with implications for pathogenesis of cardio-vascular disease. Circulation (1996) 93:1331–1333.
   PubMed Web of Science ®Google Scholar
• TURNER RC, HOLMAN RR: The UK Prospective Diabetes Study. Ann. Med. (1996) 5:439–444.
   Web of Science ®Google Scholar
• UNIVERSITY GROUP DIABETES PROGRAM: A study of the effects of hypoglycaemic agents on vascular complica-tions in patients with adult-onset diabetes. II. Mortality results. Diabetes (1970) 19:789–830.
   Google Scholar
• •• Largest (flawed) published study to date examining outcomes with respect to treatment in NIDDM.
   Google Scholar
• DEFRONZO RA, BARZILAI N, SIMONSON DC: Mechanism of metformin action in obese and lean non-insulin dependent diabetic subjects. J. Gin. Endocrin. Metab. (1991) 73:1294–1301.
   PubMed Web of Science ®Google Scholar
• HOTHER-NIELSEN 0, SCHMITZ 0, ANDERSEN PH et al: Metformin improves peripheral but not hepatic insulin action in obese patients with Type II diabetes. Acta Endocrinologica (1989) 120:257–265.
   PubMedGoogle Scholar
• BAILEY CJ, TURNER RC: Drug therapy: metformin. New Engl. J. Med. (1996) 334:574–579.
   PubMed Web of Science ®Google Scholar
• BERGER M, KOBBERLING J, WINDELER J: Appraisal of effectiveness and potential therapeutic benefit of acar-bose: a non-consensus conference (workshop report). Diabetologia (1996) 39:873–874.
   Web of Science ®Google Scholar
• FUJITA T, SUGIYAMA Y, TAKETOMI S etal: Reduction of insulin resistance in obese and/or diabetic animals by 54441-met hylcy clohexy lmethoxy) -benzyll-thiazolidi-ne-2,4-dione (ADD-3878, U-63287, Ciglitazone), a new antidiabetic agent. Diabetes (1983) 32:804–810.
   PubMed Web of Science ®Google Scholar
• SALTIEL AR, OLEFSKY JM: Thiazolidinediones in the treatment of insulin resistance and Type II diabetes. Diabetes (1996) 45:1661–1669.
   PubMed Web of Science ®Google Scholar
• CHAIKEN RL, ECKERT-NORTON M, PASMANTIER R et al: Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects. Diabetologia (1995) 38:1307–1312.
   PubMed Web of Science ®Google Scholar
• SUTER SL, NOLAN JJ, WALLACEP: Metabolic effects of new oral hypoglycaemic agent CS-045 in NIDDM subjects. Diab. Care (1992) 15:193-202. First study in human NIDDM with thiazolidinediones.
   Google Scholar
• KUMAR S, BOULTON AJM, BECK-NIEISEN H et al.: Trogli- tazone, an insulin enhancer, improves metabolic con-trol in NIDDM patients. Diabetologia (1996) 39:701–709.
   PubMed Web of Science ®Google Scholar
• IWAMOTO Y, KOSAKA K, KUZUYA T et al: Effect of combination therapy of troglitazone and sulphony-lureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diab. Med. (1996) 13:365–370.
   PubMed Web of Science ®Google Scholar
• NOLAN JJ, LUDVIC B, BEERSDEN P eta]. Improvement in glucose tolerance and insulin resistance in obese sub-jects treated with troglitazone. New Engl. J. Med. (1994) 331:1188–1193.
   Google Scholar
• ANTONUCCI T, MCLAIN R, VVHITCOMB R, LOCKWOOD D: Impaired glucose tolerance is normalised by treatment with the thiazolidinedione, troglitazone. Diab. Care (1997) 20:188–193.
   PubMed Web of Science ®Google Scholar
• BERKOWITZ K, PETERS R, KJOS SL eta].: Effect of trogli-tazone on insulin sensitivity and pancreatic beta cell function in women at high risk for NIDDM. Diabetes (1996) 45:1572–1579.
   Google Scholar
• YOSHIOKA S, NISHINO H, SHIRAKI T eta].: Antihyperten-sive effects of CS-045 treatment in obese Zucker rats. Metabolism (1993) 42:75–80.
   Google Scholar
• DUBEY RK, ZHANG HY, REDDY SR et al: Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am. J Physiol. (1993) 265:R726–R732.
   PubMed Web of Science ®Google Scholar
• OGIHARA T, RAKUGI H, IKEGAMI H eta].:Enhancement of insulin sensitivity by troglitazone lowers blood pres- sure in diabetic hypertensives. Am. J Hypertens. (1995) 8:316–320.
   Google Scholar
• GHAZZI M, PEREZ JE, ANTONUCCI TK: Cardiac and gly-caemic benefits of troglitazone treatment in NIDDM. Diabetes (1997) 46:433–439.
   PubMed Web of Science ®Google Scholar
• FRANKS S:Polycysticovarian syndrome. NewErigl. J. Med.(1995) 333:853–861.
   PubMed Web of Science ®Google Scholar
• DUNAIF A, SCOTT D, FINEGOOD D et al: The insulinsensitising agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syn-drome. J. Clin. Endocrin. Metab. (1996) 81:3299–3306.
   PubMed Web of Science ®Google Scholar
• STEVENSON RW, HUTSON NJ, KRUPP MN etal.: Actions ofnovel antidiabetic agent englitazone in hyperglycaemic ob/ob mice. Diabetes (1990) 39:1218–1227.
   Google Scholar
• IBRAHIMI A, TEBOUL L, GAILLARD D eta].: Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol (1994) 46:1070–1076.
   Google Scholar
• SCHOONJANS K, STAELS B, AUVVERX J: The peroxisome proliferator activated receptors (PPARs) and their ef- fects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta (1996) 1302:93-109. Good review of a rapidly developing field
   Google Scholar
• TONTONZ P, HU E, SPIEGELMAN BM: Regulation of adipocyte gene expression and differentiation by per-oxisome proliferator activated receptor gamma. Curr. Opin. Gen. Dev. (1995) 5:571–576.
   PubMed Web of Science ®Google Scholar
• LAMBE KG, TUGWOOD JD: The human peroxisome -p ro-liferator-activated receptor gamma is activated by in-ducers of adipogenesis, including thiazolidinedione drugs. Eur. j Biochem. (1996) 239:1–7.
   PubMedGoogle Scholar
• ELBRECHT A, CHEN Y, CULLINAN CA et al: Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gammal and gamma2. Biochem. Biophys. Res. COMMUTI. (1996) 224:431-437 Description of PPARy expression in skeletal muscle.
   Google Scholar
• NOGUCHI N, SAKAI H et al: Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis (1996) 123:227–234.
   PubMed Web of Science ®Google Scholar
• REN J, DOMINGUEZ L, SOWERS JR, DAVIDOFF AJ: Trogli-tazone attenuates high-glucose-induced abnormalities in relaxation and intracellular calcium in rat myocytes. Diabetes (1996) 45:1822–1825.
   PubMed Web of Science ®Google Scholar
• LAW RE, MEEHAN WP, XI X-P etal: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyper-plasia. j Clin. Invest. (1996) 98:1897–1905.
   PubMed Web of Science ®Google Scholar
• STEPHENS TW, BERGMAN JA, BUE-VALLESKY JM et al: Thiazolidinedione induced cardiac biochemical changes and increased IGF-1 action on cardiomyocyt es [abstract]. Diabetologia (1995) 38:51.
   Google Scholar
• RACHMAN J, TURNER RC: Drugs on the horizon for the treatment of Type 2 diabetes. Diab. Med. (1995) 12:467–478.
   PubMed Web of Science ®Google Scholar
• KATO K, NAKAYAMA K, OHTA M et al: Effects of novelaldose reductase inhibitors M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur. j Pharmacol. (1991) 193:185–191.
   PubMed Web of Science ®Google Scholar
• NICOLUCCI A, CARINCI F, CAVALIERE D et al.: A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. Diab. Med. (1996) 12:1017–1026.
   Web of Science ®Google Scholar
• NAKAYAMA K, MURAKAMI N, OHTA M et al.: Antihyper-glycaemic effects of M16209, a novel aldose reductase inhibitor, in normal and diabetic rats. Eur. J. Pharmacol (1995) 276:77–83
   PubMed Web of Science ®Google Scholar
• OHTA M, MURAKAMI M, KATO K et al: Effects of M16209,a new antihyperglycaemic agent, on insulin sensitivity in vivo: euglycaemic clamp studies in rats. Metabolism (1996) 4:1095–1100.
   Web of Science ®Google Scholar
• MURAKAMIN, OHTA M, HASHIMOTO K et al.: Ameliora-tion of insulin resistance in genetically obese rodents by M16209, a new antidiabetic agent. Eur. j Pharmacol (1996) 304:129–134.
   PubMed Web of Science ®Google Scholar
• KROTKIEWSKI M, MANDROUKAS K, SJOSTROM L et al.: Effects of long-term physical baining on body fat, metabolism and blood pressure in obesity. Metabolism (1979) 28:650–658.
   PubMed Web of Science ®Google Scholar
• PETRIE JR, DONNELLY R: New pharmacological ap-proaches to insulin and lipid metabolism. Drugs (1994) 47:701–710.
   PubMed Web of Science ®Google Scholar
• HOLLENGMA C, ZAAGSMA J: Direct evidence for the a typical nature of functional beta-receptors in rat adipocytes. Br. J. Pharmacol. (1989) 98:1420–1424.
   Google Scholar
• EMORINE JL, MARULLO S, BRIEND-SUTREN MM et al:
   Google Scholar
• •Molecular characterisation of the human beta3-adren-ergic receptor. Science (1989) 245:1118–1121.
   PubMed Web of Science ®Google Scholar
• BERKOWITZ DE, NARDONE NA, SMILEY RM et al.: Distri- bution of beta3-adrenoceptor mRNA in human tissues. Eur. J. Pharmacol (Mol. Pharmacol. Section) (1995) 289:223–228.
   PubMed Web of Science ®Google Scholar
• LIPWORTH BJ: Clinical pharmacology of beta3-adreno-ceptors. Br. J. Pharmacol (1996) 42:291–300
   Web of Science ®Google Scholar
• CAWTHORNE MA, SENNIN MV, ARCH JRS, SMITH SA: B11135135, a potent and selective atypical beta-adreno-ceptor agonist. Am. J. Clin. Nut. (1992) 55:252S–257S.
   Google Scholar
• FISHER LG, SHER PM, SKWISH S et al.: BMS-187257, a potent, selective and novel heterocyclic beta3 adrener-gic receptor agonist. Bioorg. Med. Chem. Lett. (1996) 6(19)2253–2258.
   Google Scholar
• HIOKI Y, ITOH Y, NAKAJIMA A et al: A novel adrenaline agent, AZ0002 and its hypoglycaemic action in yellow KK mice. Pharmacology (1995) 69(3):251.
   Web of Science ®Google Scholar
• FULCHER GR, ALBERTI KGMM: Hypoglycaemic action of antilipolytic agents. In: New Antidiabetic Drugs. Bailey .3,z Flatt (Eds.), Smith Gordon, London (1990):143–155.
   Google Scholar
• DAVOREN PM, MOTALA A, ALBERTI KGMM: The effect ofacipimox on glucose disposal in non-insulin dependent diabetes is dependent on the lowering of non-esterifled fatty acid levels. Diab. Nuft-. Metab. (Clin. Exper.) (1995) 8:99–104.
   Web of Science ®Google Scholar
• DAVOREN PM, ALBERTI KGMM: The effect of 24-hour suppression of plasma non-esterifled fatty acid levels on glucose and lipid metabolism in NIDDM. Diab. Nair. Metab. (Clin. Exper.) (1995) 8:17–23.
   Web of Science ®Google Scholar
• WEBSTER JM, HESELTINE L, TAYLOR R: In vitro effect of adenosine agonist GR79236 on the insulin sensitivity of glucose utilisation in rat soleus and human rectus abdominus muscle. Biochim. Biophys. Acta (1996) 1316:109–113.
   PubMed Web of Science ®Google Scholar
• HESELTINE, L, WEBSTER JM, TAYLOR R: Adenosine effectsupon insulin action on lipolysis and glucose transport in human adipocytes. Mol Cell. Biochem. (1995) 144:147–151.
   PubMed Web of Science ®Google Scholar
• BAILEY CJ, PAGE T, DAY C, THORNBURN CC: Acute effectof benfluorex onglucose metabolism. Biochem. Pharma-col. (1992) 44:379–382.
   PubMed Web of Science ®Google Scholar
• PONTIROLI, AE, PACCHIONI M, PIATTI PM et al: Benfluo-rex in obese Type II diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. J. Clin. Endocrin. Metab. (1996) 81:3727–3732.
   PubMed Web of Science ®Google Scholar
• STACPOOLE PW, GREENE YJ: Dichloroacetate. Diab. Care(1992) 785–791.
   PubMed Web of Science ®Google Scholar
• BRYER-ASH M, FOLLETT L, HODGES N, WIMALAWANSA S:Amylin-mediated reduction in insulin sensitivity corre-sponds to reduced insulin receptor-kinase activity in the rat in vivo. Metabolism (1995) 44:705–711.
   PubMed Web of Science ®Google Scholar
• ESPINAL J, LACOUR F, BERGER S, DUHAULT J: S15261antagonises amylin-induced impaired glucose toler-ance. FEBS Lett. (1995) 368:36–38.
   PubMed Web of Science ®Google Scholar
• WILDING JPH, KHANDANNIA N, BENNET VVM: Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during euglycaemic hyperinsulinae-mic clamp in humans. Diabetologia (1994) 37:166–169.
   PubMed Web of Science ®Google Scholar
• BRICHARD SM, HENQUIN J-C: The role of vanadium in the management of diabetes. Trends Pharmacol Sci. (1995) 16:265–270.
   PubMed Web of Science ®Google Scholar